Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

IMA new masthead1

Internal Medicine Alert – December 30, 2023

December 30, 2023

View Archives Issues

  • Who Benefits Most from Tirzepatide Among Patients with Type 2 Diabetes?

    Females, patients of white or Asian race, younger patients, and those taking metformin benefit the most from treatment with tirzepatide.

  • Peak SARS-CoV-2 Viral Loads Delayed

    In an effort to characterize the hypothetical utility of rapid COVID-19 antigen kits, the authors of this study examined cycle threshold values in symptomatic adults infected with SARS-CoV-2 relative to the onset of symptoms.

  • Slow-Wave Sleep and Risk of Dementia

    In this long-term observational study of sleep efficiency in the Framingham Heart Study population, researchers found a strong correlation between a decline in duration of slow-wave sleep during aging and the risk of incident dementia from all causes. However, a direct cause-and-effect relationship cannot be determined from this observational study.

  • Apixaban Dose in Atrial Fibrillation Patients with Chronic Kidney Disease

    A large nationwide health systems database study comparing 5 mg apixaban vs. 2.5 mg twice daily in patients with stage 4/5 chronic kidney disease not on dialysis shows that the 5 mg dose increases the risk of bleeding compared to 2.5 mg without any improvement in the risk of stroke, systemic emboli, or death.

  • Treatable Causes of Rapidly Progressive Dementias

    Many cases of rapidly progressive dementia are caused by prion diseases and have no effective treatments. But, with the greater awareness of the presentation for autoimmune encephalitis, these disorders make up an increasing percentage of presenting cases and can be aggressively and successfully treated. The STAM3P score helps to identify potentially treatable cases of this disorder.

  • Vonoprazan Fumarate Tablets (Voquezna)

    The U.S. Food and Drug Administration has approved vonoprazan for the treatment of all grades of erosive esophagitis. Vonoprazan is a potassium-competitive acid blocker that originally was approved in 2022 for use in combination with amoxicillin or with amoxicillin and clarithromycin for the treatment of Helicobactor pylori infection.